Chart, page-2515

I think this post I made from December is especially relevant now that ANP has broken over the 16.5c major resistance

Re-rate is on & similar to RHY, it could now 10x over the coming months

SRPT's spectacular failure re: Gene Therapy avenue for DMD treatment is an enormous milestone for ANP given they lost US$8B in mkt cap overnight and now are going to need to find a way to 'protect their DMD revenue moat'

Corporate action (near term) for ANP would not surprise in the slightest, especially given SRPT is sitting on US1.5B in cash

Then, of course, lets not forget the position Roche is now in due to SRPT's failure (Roche was a party to the gene therapy drug)

Stars are aligned